Prolonged serum half‐life is required for the efficacy of most protein therapeutics. One strategy for half‐life extension is to exploit the long circulating half‐life of serum albumin by incorporating a binding moiety that recognizes albumin. Here, we describe camelid single‐domain antibodies (VHHs) that bind the serum albumins of multiple species with moderate to high affinity at both neutral and endosomal pH and significantly extend the serum half‐lives of multiple proteins in rats from minutes to days. We serendipitously identified an additional VHH (M75) that is naturally pH‐sensitive: at endosomal pH, binding affinity for human serum albumin (HSA) was dramatically weakened and binding to rat se... More
Prolonged serum half‐life is required for the efficacy of most protein therapeutics. One strategy for half‐life extension is to exploit the long circulating half‐life of serum albumin by incorporating a binding moiety that recognizes albumin. Here, we describe camelid single‐domain antibodies (VHHs) that bind the serum albumins of multiple species with moderate to high affinity at both neutral and endosomal pH and significantly extend the serum half‐lives of multiple proteins in rats from minutes to days. We serendipitously identified an additional VHH (M75) that is naturally pH‐sensitive: at endosomal pH, binding affinity for human serum albumin (HSA) was dramatically weakened and binding to rat serum albumin (RSA) was undetectable. Domain mapping revealed that M75 bound to HSA domain 1 and 2. Moreover, alanine scanning of HSA His residues suggested a critical role for His247, located in HSA domain 2, in M75 binding and its pH dependence. Isothermal titration calorimetry experiments were suggestive of proton‐linked binding of M75 to HSA, with differing binding enthalpies observed for full‐length HSA and an HSA domain 1‐domain 2 fusion protein in which surface‐exposed His residues were substituted with Ala. M75 conferred moderate half‐life extension in rats, from minutes to hours, likely due to rapid dissociation from RSA during FcRn‐mediated endosomal recycling in tandem with albumin conformational changes induced by M75 binding that prevented interaction with FcRn. Humanized VHHs maintained in vivo half‐life extension capabilities. These VHHs represent a new set of tools for extending protein therapeutic half‐life and one (M75) demonstrates a unique pH‐sensitive binding interaction that can be exploited to achieve modest in vivo half‐life.
